Biosimilar medicines
A look at Teva Canada’s biosimilars
As biosimilars gain importance in the Canadian market, we at Teva Canada are dedicated to expanding our portfolio to deliver innovative biosimilars that you can trust.We are committed to growing our already expansive portfolio of over 1,800 brand-name and generic medicines by investing in the future of biosimilar medicines in Canada, with expertise, experience and dedication you can trust.
Manufactured in state-of-the-art facilities and made with the highest quality agents, Teva Canada’s biosimilars deliver safety and efficacy in the treatment of non-Hodgkin’s lymphoma, chronic lymphoblastic leukemia, breast cancer and more.
Go Behind the Scenes at Teva’s state-of-the-art biopharmaceutical facility in Ulm, Germany. Discover more about biosimilars and meet the experts who are advancing more treatment options for patients.
Behind the Scenes - 'Looking After The Little Things'
Go Behind the Scenes at Teva’s state-of-the-art biopharmaceutical facility in Ulm, Germany. Discover more about biosimilars and meet the experts who are advancing more treatment options for patients.
Explore Teva Canada’s biosimilars
Teva Canada is proud to be actively shaping the biosimilars market with innovative medicines.Resources
Teva Canada knows you or your loved ones may have questions regarding the safety and efficacy of biosimilars. Here are some resources to help you better understands these biologic medicines.
The Canadian Agency for Drugs and Technology in Health (CADTH)
Useful information on safety, effectiveness and benefits of biosimilars.